Gender-based violence (GBV) and intimate partner violence (IPV) pose significant barriers to effective HIV prevention, including PrEP services. This overview highlights the importance of routine inquiry for GBV in PrEP programs to enhance PrEP uptake and adherence, especially among vulnerable popula

1 views • 27 slides

This update highlights key points from the PMK No. 23/2022 on combating HIV, AIDS, and STIs. It covers terminologies, goals for eliminating HIV and AIDS by 2030, and strategies such as PrEP and PEP. The guidelines emphasize timely interventions like Post-Exposure Prophylaxis (PEP) and Pre-Exposure P

3 views • 38 slides

HIV and AIDS are closely related, with HIV being the virus that leads to AIDS. HIV weakens the immune system by attacking specific white blood cells, while AIDS is the advanced stage of HIV infection. Prevention is crucial as AIDS is a deadly, incurable disease. The transmission of HIV primarily occ

4 views • 14 slides

HIV, a member of the lentivirus subfamily of retroviruses, causes Acquired Immunodeficiency Syndrome (AIDS). HIV-1 and HIV-2 have distinct characteristics, with HIV-1 being global and HIV-2 primarily in West Africa. The virus encodes reverse transcriptase and has an envelope containing glycoproteins

1 views • 31 slides

HIV Post-Exposure Prophylaxis (PEP) is a crucial emergency medical response for individuals exposed to HIV, aiming to prevent infection. It involves a regimen of medications, tests, and counseling services initiated within 72 hours of exposure. HIV transmission occurs through body fluids like blood,

3 views • 27 slides

This content provides an overview of the relationship between TB and HIV, emphasizing the importance of testing HIV patients for latent TB infection and TB patients for HIV. It also outlines the guidelines for managing these co-infections, including diagnostic tests, treatment strategies, and patien

0 views • 17 slides

PEPFAR is intensifying efforts on partner notification services for HIV prevention to address the global issue of undiagnosed HIV cases. The initiative aims to improve testing strategies, increase testing volumes, and enhance epidemic control. By reaching HIV testing targets and implementing efficie

0 views • 24 slides

This study led by Dr. Geoffrey Chipungu, an HIV/AIDS Specialist at UNICEF ESARO, explores the rates, trends, and factors associated with HIV viral load suppression (VLS) in children. The research reveals sub-optimal VLS rates in children compared to adults, highlighting the need for improved policie

5 views • 12 slides

HIV, Human Immunodeficiency Virus, attacks the immune system and can progress to AIDS if left untreated. Antiretroviral Therapy (ART) helps control HIV, allowing individuals to live healthy lives. The stages of HIV include Acute Infection, Chronic Infection, and the most severe stage, AIDS. Early de

0 views • 29 slides

This content provides detailed instructions for conducting HIV rapid tests using three different kits: Determine HIV-1/2 Rapid Test, Uni-Gold HIV-1/2 Rapid Test, and Bioline HIV-1/2 Rapid Test. The instructions include steps such as specimen collection, test device preparation, result interpretation

0 views • 5 slides

Analysis conducted by the PROMISE Consortium in January 2022 highlights the prioritized counties for introducing the monthly dapivirine ring as an HIV prevention method for women in Kenya. The scenarios consider HIV incidence among women and current oral PrEP uptake across counties to determine the

0 views • 9 slides

HPTN 069/ACTG A5305 is a Phase II study evaluating the safety and tolerability of Maraviroc (MVC)-containing regimens compared to Tenofovir/emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) in at-risk women. The study involves a randomized, double-blind, placebo-controlled design with

0 views • 18 slides

August 18, 2020, marked the 30th anniversary of the Ryan White CARE Act, a landmark legislation that established the Ryan White HIV/AIDS Program providing care and treatment services to individuals with HIV in the U.S. The Act has been amended several times to extend and revise its purpose, no longe

0 views • 21 slides

This training session focuses on the relationship between undernutrition and HIV, discussing how HIV/AIDS affects nutrition among People Living with HIV (PLHIV). It covers the benefits of good nutrition for PLHIV and provides recommendations for Nutrition Assessment, Counselling, and Support (NACS)

1 views • 27 slides

In response to the HIV/AIDS pandemic, this study focuses on the effectiveness of Pre-Exposure Prophylaxis (PrEP) in reducing HIV transmission among African American men who have sex with men in Orangeburg, SC. The research aims to investigate the impact of PrEP compared to condom use, and the necess

0 views • 6 slides

Maria, a pregnant woman in Malawi, faces the challenge of an unexpected pregnancy and a positive HIV diagnosis. The scenario explores her concerns, midwifery diagnosis, preparation for HIV testing, disclosure of results, and maintaining confidentiality in antenatal care. It also delves into factors

0 views • 10 slides

12.7 million people worldwide inject drugs, with 1.7 million of them living with HIV. The prevalence of HIV among people who inject drugs is 13.1%, highlighting the need for comprehensive service provision including testing, needle programs, opioid therapy, and antiretroviral treatment. The data als

0 views • 4 slides

This presentation highlights the significance of Regenerating Islet-Derived Protein-3 (REG3) and Intestinal Fatty Acid Binding Protein (I-FABP) in microbial translocation, inflammation, and reservoir size in individuals living with HIV. REG3 and I-FABP serve as markers of gut epithelial damage and p

0 views • 7 slides

PrEP is a vital HIV prevention strategy; however, individuals with Acute HIV Infection (AHI) may inadvertently start PrEP due to the limitations of current screening methods. The ImPrEP project in Brazil, Mexico, and Peru aims to evaluate the feasibility of providing PrEP to MSM and transgender indi

0 views • 15 slides

Global declines in HIV testing and reductions in new initiators, coupled with disruptions in HIV services due to COVID-19, pose challenges for future healthcare. Short-term disturbances could lead to increased HIV-related mortality, emphasizing the need for program responses to mitigate adverse effe

0 views • 10 slides

HIV/AIDS presents complex medical and psychiatric challenges, including HIV-Associated Neurocognitive Disorders (HANDs), which impact patients, families, and caregivers. This presentation by Dr. Mary Ann Adler Cohen provides insights into the prevalence, impact, diagnosis, and treatment of HANDs, em

0 views • 56 slides

Study on long-acting lenacapavir in heavily treatment-experienced HIV individuals after 104 weeks revealed emergence of lenacapavir resistance-associated mutations. Lenacapavir, a potent HIV-1 capsid inhibitor, has shown activity against ARV-resistant strains. The CAPELLA study analyzed lenacapavir

0 views • 11 slides

The collaborative regional convening in Ghana focused on the CHOICE Manifesto, advocating for choice in HIV prevention tools for women and girls in Southern and Eastern Africa. The SANAC Women's Sector emphasized the need for a comprehensive approach to address the ongoing threat of HIV, calling for

0 views • 9 slides

Hypothesized peer-led community-based provision of PrEP services positively influenced PrEP uptake among female sex workers in Zimbabwe. Despite national commodity shortages, PrEP initiation rates peaked at 51% in September 2020, with 33.7% of 19,407 sex workers initiating PrEP. The highest initiati

0 views • 9 slides

This session introduces basic epidemiological concepts, differentiates between HIV and AIDS, explains the HIV life cycle, and discusses how HIV is transmitted. Definitions of key terms like prevalence, incidence, mortality rate, and morbidity are provided. The session also highlights the differences

0 views • 30 slides

The V3 region of gp120 plays a crucial role in HIV entry to CD4 T-cells by determining the coreceptor usage. Studies focus on the structural aspects of V3, its conservation, coreceptor binding, and antibody accessibility. The HIV envelope structure, including trimeric spikes with gp120 and gp41 glyc

0 views • 24 slides

Conduct a data-driven assessment of HIV prevention programme needs and barriers in Ghana based on the Ghana Road Map Baseline Survey components. Evaluate the country's preparedness in addressing HIV epidemic patterns and prevention response analysis. Identify key barriers hindering HIV prevention ef

0 views • 11 slides

Pooled data from 11 F/TDF demonstration projects involving over 6000 cisgender women over eight years examined adherence and HIV incidence. The study aimed to assess the effectiveness of F/TDF for HIV prevention in real-world settings, revealing adherence patterns in a subset of participants. This r

0 views • 16 slides

Learn about important factors to consider when providing oral PrEP to adolescent girls and young women (AGYW), including combination prevention services and entry points, evidence gathering, and initiation and clinical management of oral PrEP. Discover related services alongside oral PrEP, opportuni

0 views • 15 slides

Uganda has been proactive in implementing oral PrEP as a key biomedical prevention intervention since December 2016. Dr. Herbert Kadama, on June 18, 2019, provided updates on the progress of the PrEP program in Uganda. The country has developed a comprehensive road map for PrEP implementation, cover

0 views • 16 slides

The study focuses on initiating combination antiretroviral therapy for all HIV-infected individuals to preserve the CD4+ T cell population, restrict viral reservoir seeding, and minimize viral evolution. Rapid suppression of HIV viraemia in patients could lead to potential candidates for future cure

0 views • 12 slides

Guidelines for Oral PrEP eligibility criteria, kidney function monitoring during initiation and follow-up visits, recommendations for starting and stopping Oral PrEP based on different populations, and included groups. Emphasis on kidney health and regular creatinine clearance evaluation. Effective

0 views • 13 slides

Explore eligibility criteria and dosing guidelines for Event-Driven PrEP (ED-PrEP), a preventive medication regimen for individuals at substantial risk for HIV infection. Learn who is eligible, dosing instructions, and how to determine eligibility through specific questions.

0 views • 16 slides

These guidelines aim to increase awareness and knowledge of PrEP efficacy, assist clinicians in identifying candidates for PrEP, address barriers to access, and provide evidence-based recommendations for PrEP initiation, management, monitoring, and more. Key points include same-day initiation of PrE

0 views • 60 slides

This study aims to describe real-world use patterns and HIV seroconversion rates for individuals using emtricitabine/tenofovir disoproxil fumarate (F/TDF) vs. emtricitabine/tenofovir alafenamide (F/TAF) as pre-exposure prophylaxis (PrEP) for HIV prevention. The retrospective analysis includes newly

0 views • 9 slides

In Botswana, there is a significant HIV prevalence among young women and men, with specific focus on the lack of PrEP implementation. The country is lagging behind others like South Africa and Kenya in rolling out PrEP to the general population. Education on PrEP is crucial, targeting young people,

0 views • 9 slides

Learn about the importance of Pre-Exposure Prophylaxis (PrEP) for preventing HIV acquisition in sexually active individuals, including the need for HIV testing, indications for PrEP, and identifying acute HIV infection. This guide emphasizes the significance of offering PrEP to all at-risk individua

0 views • 31 slides

In this presentation by Dr. Raphael J. Landovitz, key topics covered include recommended options for PrEP agent choice, guidelines comparisons, and expert clinical resources. The case of Angeline, a transfeminine patient considering HIV prevention, is highlighted. New updates for 2022 on PrEP option

0 views • 18 slides

This presentation by Dr. Ricardo A. Franco focuses on the challenges faced in managing and treating patients with HIV/Hepatitis C virus coinfection. It discusses the burden of HCV mono-infection and HIV/HCV co-infection, the impact of HIV co-infection on survival in HCV-related cirrhosis, and the ro

0 views • 26 slides

PrEP Scale Up in Kenya: Bridge to Scale Project sessions in 2017 discussed the National HIV Prevalence, PrEP journey, TWG composition, milestones, sub-committees, and outputs focusing on scaling up PrEP as an effective HIV-prevention intervention.

0 views • 20 slides